|

Osimertinib Mesylate Tablets Clinical Trials

3 actively recruiting trials

Pipeline

Phase 2: 2Phase 3: 1

Top Sponsors

  • Sichuan Baili Pharmaceutical Co., Ltd.1
  • Shanghai Hengrui Pharmaceutical Co., Ltd.1
  • Allist Pharmaceuticals, Inc.1

Indications

  • Cancer3
  • Lung Cancer2
  • NSCLC Patients With Brain Metastasis1
  • Advanced Solid Tumors1
  • Non Small Cell Lung Cancer1

Other3 trials

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Phase 3
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.